Cefepime: a reappraisal in an era of increasing antimicrobial resistance.
Cefepime is a 'fourth-generation' cephalosporin with an in vitro extended-spectrum of activity against Gram-negative and Gram-positive pathogens. Cefepime is approved for the treatment of moderate-to-severe infections, such as pneumonia, uncomplicated and complicated urinary tract infections, skin and soft-tissue infections, intra-abdominal infections and febrile neutropenia. In this article, we provide a critical review of pharmacodynamics, clinical management, pharmacokinetics, metabolism, pharmacodynamic target analyses, clinical efficacy, safety and tolerability of cefepime after more than a decade of clinical use.
Endimiani
Andrea
A
Department of Medicine, Section of Infectious Diseases, Case Western Reserve University, School of Medicine, Cleveland, OH, USA. aendimiani@gmail.com
Perez
Federico
F
Bonomo
Robert A
RA
D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D000077723:Cefepime; D002511:Cephalosporins / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D024881:Drug Resistance, Bacterial; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000472:pathogenicity; D006094:Gram-Positive Bacteria / Q000187:drug effects / Q000472:pathogenicity; D006801:Humans; D012189:Retrospective Studies
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000077723:Cefepime